{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-25-000053","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.505213+00:00","generated_at":"2026-05-22T00:40:20.809693+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biohaven Q1 net loss $221.7M; announces $600M Oberland capital deal for troriluzole launch","bullets":["Net loss of $221.7M ($2.17 per share); non-GAAP adjusted net loss $166.8M ($1.64 per share).","Cash as of April 30, 2025: ~$518M, after receiving $250M first tranche from Oberland Capital.","$600M non-dilutive note purchase with Oberland; includes regulatory milestone and royalty on troriluzole sales.","Troriluzole NDA for SCA under FDA priority review; PDUFA in Q3 2025; mid-cycle review completed without advisory committee.","Upcoming milestones: pivotal topline data for troriluzole in OCD in 1H 2025, BHV-7000 MDD data in 2H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-25-000053","json":"https://secwatch.observer/filing/0001935979-25-000053.json","markdown":"https://secwatch.observer/filing/0001935979-25-000053.md","text":"https://secwatch.observer/filing/0001935979-25-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597925000053/0001935979-25-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597925000053/bhvn-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:40:20.809693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}